A view from the Center


Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Digital tech and strong patient-advocacy partnerships could be a win-win-win for pharma, advocacy groups, and patients

by Jonathan Fox, Specialist leader, Deloitte Consulting LLP

I’m in Philadelphia this week for the annual EyeForPharma conference where I’ll be moderating a panel looking into how pharmaceutical companies and advocacy groups can take their relationship to the next level. Both sides have something to gain, and the patient could be the biggest winner.

Pharmaceutical companies often collaborate with patient advocacy groups,

Read more

Provider-sponsored health plans can be at the forefront of the changing health care market

by Maulesh Shukla, Assistant Manager, Deloitte Consulting LLP

I have always been fascinated by simple solutions to seemingly complex problems. Few problems are more vexing than the US health care system. One of the solutions offered by several experts and policy makers is unifying care delivery and financing. Isn’t that simple? If not the solution, at least the articulation of the solution is simple.

Read more

As our parents age, health care stakeholders should determine how to connect with them…and with us (their caregivers)

by Claudia Douglass, Managing Director, Deloitte Consulting LLP

My mother and I have completely different health needs, we don’t engage with the health care system the same way, and we have vastly different expectations. My mom is 91, nearly blind, and spends her days at an assisted living facility. While I am continually connected to technology, she goes out of her way to avoid it…although she does make an exception to watch Family Feud every evening.

Read more

The five Cs of disruption

by Pete Micca, Partner, Deloitte & Touche LLP

What’s shaping the future of health tech investment?


Health care technology investment in 2017 appeared to be all about convergence. In fact, there were no health tech IPOs at all that year.1 The focus seemed to be squarely on expanding industry footprints to gain economies of scale and more control over the continuum of health services.

Read more